Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MTAP (Methylthioadenosine Phosphorylase)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

GALEAS™ Hereditary Plus

GALEAS™ Hereditary Plus

›

MTAP deletion	Non Small Cell Lung Cancer	MTAP deletion	Non Small Cell Lung Cancer	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2	IDE397 Sensitive: C2 – Inclusion Criteria IDE397 Sensitive : C2
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2
PRMT5 overexpression + MTAP deletion	Mantle Cell Lymphoma	PRMT5 overexpression + MTAP deletion	Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
CDKN2A deletion + MTAP deletion	Mantle Cell Lymphoma	CDKN2A deletion + MTAP deletion	Mantle Cell Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
MTAP deletion	Urothelial Cancer	MTAP deletion	Urothelial Cancer	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
MTAP deletion	Lung Adenocarcinoma	MTAP deletion	Lung Adenocarcinoma	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3	pemetrexed Sensitive: C3 – Early Trials pemetrexed Sensitive : C3
MTAP mutation	Squamous Cell Carcinoma of Head and Neck	MTAP mutation	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3
MTAP deletion	Squamous Cell Carcinoma of Head and Neck	MTAP deletion	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3	pembrolizumab + afatinib Resistant: C3 – Early Trials pembrolizumab + afatinib Resistant : C3
MTAP mutation + CDKN2A mutation	Urothelial Cancer	MTAP mutation + CDKN2A mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MTAP mutation + CDKN2A mutation	Melanoma	MTAP mutation + CDKN2A mutation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MTAP mutation	Urothelial Cancer	MTAP mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3